Feature | March 21, 2013

ACC/HRS Release Appropriate Use Criteria for ICDs, CRT

Document examines potential clinical scenarios to support physician decision-making

ACC HRS Appropriate Use Criteria ICDs CRTs

March 21, 2013 — The American College of Cardiology (ACC) and Heart Rhythm Society (HRS), along with key specialty societies, released appropriate use criteria for implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices. The document provides assessed levels of appropriateness for implanting the devices in 369 real-life clinical scenarios, with the goal of enhancing physician and patient decision-making and improving care and health outcomes.

ICDs monitor the heart’s rhythms and correct arrhythmias (abnormal heartbeats) by providing electrical pulses to the heart. By immediately responding to any abnormal rhythm, ICDs help prevent sudden cardiac death. CRT uses an implantable device to synchronize the beating of the heart’s left and right ventricles. This improves the heart’s efficiency and reduces its stress. While both ICDs and CRT have expanded treatment options for cardiac patients, the ACC and HRS examined their use as part of an ongoing effort to critically and systematically review the diagnostic tests and procedures involved in cardiovascular care.

The criteria focus on scenarios that were derived from physician experience, clinical practice guidelines and results of studies examining device implantation. The scenarios identify “real-life” clinical situations encountered in daily practice. These clinical presentations include patients that may not be specifically covered by clinical guidelines, which the organizations hope will provide valuable assistance for decision-making by physicians and patients.

“The goal of this document is to help inform medical decisions and assist clinicians and stakeholders in understanding areas of both consensus and uncertainty, while identifying areas where there are gaps in knowledge that warrant further research,” noted Andrea M. Russo, writing committee co-chair and director of electrophysiology and arrhythmia services at Cooper University Hospital.

The scenarios cover six areas: ICDs for secondary prevention, ICDs for primary prevention, co-morbidities, CRT devices, generator replacement, and dual- versus single-chamber ICDs.

A 10-member writing committee drafted the scenarios, while a separate technical panel rated each on a numerical scale as “Appropriate” (median 7 to 9), “May Be Appropriate” (median 4 to 6), or “Rarely Appropriate” (median 1 to 3). Of the 369 scenarios, 45 percent were deemed Appropriate, 33 percent were rated May Be Appropriate, and 22 percent were determined Rarely Appropriate.

The writing committee stated that the appropriate use criteria can help inform the decision-making process but should not be used as a substitute for careful clinical judgment and clinical practice experience, nor current coverage and reimbursement policies.

“The decision to implant an ICD or CRT device is often complex, based on clinical evidence and clinical judgment, while taking into account co-morbidities and other individual patient factors,” said Russo. “While this document was designed to help inform clinical decision-making, it does not establish ‘rules’ by which decisions should be made in clinical practice. Healthcare providers and other stakeholders should continue to acknowledge the pivotal role of clinical judgment in determining whether device implantation is indicated for an individual patient.”

Russo added that the appropriate use criteria “can also be used to create algorithms or educational tools that help identify resource utilization or variations in care.” These tools can be used at the point of care — such as hospitals or physician offices — where utilization decisions are made. Data generated from these tools or collected in registries can be used to identify the patient mix for these procedures for individual institutions. This information can then be used for benchmarking over time and for comparison to other organizations.

The work of the writing committee and technical panel was supported exclusively by the ACC, the HRS and the other partnering societies without commercial support. All members were required to disclose industry relationships, which were reviewed by the Appropriate Use Criteria Task Force.

The "ACCF/HRS/AGS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy" is published on the websites of both the ACC and the HRS and will be published in the March 26, 2013 print issue of the Journal of the American College of Cardiology.

For more information: www.cardiosource.org/acc, www.hrsonline.org

Related Content

CardioKinetix, Parachute device, heart failure, 500th implantation, PARACHUTE IV Trial
News | Heart Failure| July 22, 2016
CardioKinetix Inc. announced this week that 500 patients have received the company’s Parachute Ventricular Partitioning...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing| July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
anticoagulants, dabigatran, Pradaxa, novel oral anticoagulants, NOACs, rivaroxaban, Xarelto, apixaban, Eliquis
Feature | Antiplatelet and Anticoagulation Therapies| July 12, 2016 | Heidi Olsen, Pharm.D
With the recent introduction of several novel oral...
University of Guelph study, heart failure risk, gender, aging
News | Heart Failure| July 08, 2016
University of Guelph researchers have uncovered a possible clue as to why women have lower rates of heart failure than...
Abbott, FIRM-guided rotor ablation, atrial fibrillation, clinical studies, Cardiostim 2016
News | EP Mapping and Imaging Systems| July 07, 2016
July 7, 2016 — Abbott recently announced positive results from three clinical studies investigating the benefits asso
SynCardia acquired, Versa Capital Management, chapter 11
News | Business| July 07, 2016
SynCardia Systems Inc. announced that it has entered into an asset purchase agreement (“APA”) with an affiliate of...
AtriCure, AtriClip PRO2 LAA Exclusion System, CE Mark, left atrial appendage occlusion
News | Left Atrial Appendage (LAA) Occluders| July 05, 2016
AtriCure Inc. announced that it has received CE Mark for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System...
News | Heart Failure| July 05, 2016
A research team has developed a new electric mesh device that can be wrapped around the heart to deliver electrical...
HeartWare, HVAD, batteries recall
News | Ventricular Assist Devices (VAD)| July 05, 2016
HeartWare Inc. announced a recall of the batteries used on the HeartWare Ventricular Assist Device (HVAD) because the...
anabolic steroid abuse, ARVC, arrhythmia, stroke, British Cardiovascular Society conference
News | Cardiac Diagnostics| July 01, 2016
Research has already shown that taking anabolic steroids is associated with high blood pressure and an increased risk...
Overlay Init